Innoviva (INVA) Work In Process (2012 - 2026)
Innoviva's (INVA) quarterly Work In Process came in at $17.3 million in Q1 2026, down 36.84% YoY from $27.4 million in Q1 2025, and down 3.07% on a QoQ basis from $17.9 million in Q4 2025.
Innoviva (INVA) Work In Process (2012 - 2026) Analysis & Trends
Innoviva (INVA) has 8 years of Work In Process data on file, last reported at $17.3 million in Q1 2026.
- Quarterly Work In Process fell 36.84% year-over-year to $17.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.3 million (down 36.84% YoY) and the FY2025 annual result came in at $17.9 million, down 12.95% from the prior year.
- Work In Process fell to $17.3 million in Q1 2026, from $17.9 million in the prior quarter.
- In the past five years, Work In Process ranged from a high of $54.1 million in Q3 2022 to a low of $13.2 million in Q3 2023.
- A 5-year average of $23.6 million and a median of $20.5 million in 2024 frame the typical range for Work In Process.
- Annual changes were most pronounced in 2023 — Work In Process slumped 75.56% — and 2024, when it jumped 54.18%.
- Tracing INVA's Work In Process over 5 years: stood at $25.1 million in 2022, then sank by 37.45% to $15.7 million in 2023, then surged by 31.01% to $20.5 million in 2024, then fell by 12.95% to $17.9 million in 2025, then fell by 3.07% to $17.3 million in 2026.
- The last three Work In Process figures came in at $17.3 million (Q1 2026), $17.9 million (Q4 2025), and $18.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.12 Mn |
| Mar 31, 2026 | 17.32 Mn |
| Dec 31, 2025 | 17.87 Mn |
| Sep 30, 2025 | 18.67 Mn |
| Jun 30, 2025 | 34.15 Mn |
| Mar 31, 2025 | 27.43 Mn |
| Dec 31, 2024 | 20.53 Mn |
| Sep 30, 2024 | 20.40 Mn |
| Jun 30, 2024 | 22.80 Mn |
| Mar 31, 2024 | 20.20 Mn |
| Dec 31, 2023 | 15.67 Mn |
| Sep 30, 2023 | 13.23 Mn |
| Jun 30, 2023 | 23.87 Mn |
| Mar 31, 2023 | 22.54 Mn |
| Dec 31, 2022 | 25.05 Mn |
| Sep 30, 2022 | 54.13 Mn |
| Mar 31, 2014 | 2.23 Mn |
| Dec 31, 2013 | 360,000.00 |
| Sep 30, 2013 | 3.61 Mn |
| Jun 30, 2013 | 4.71 Mn |